ON MAY 30, the American Cancer Society announced a change in its guidelines for colon cancer screening. The ACS now recommends starting screening at age 45, instead of 50.
Imagine a better, easier, cheaper and less invasive and time-consuming way to do a colonoscopy. Well, there is, and it’s a good thing, too, since colon and rectal cancer kills more than 50,000 people a year. Yet, shockingly, as Dr. Klein and his co-authors describe below, the federal agency overseeing Medicare and Medicaid is dragging its feet on approving this proven alternative called virtual colonoscopy.
ON MAY 30, the American Cancer Society announced a change in its guidelines for colon cancer screening (https://doi.org/10.3322/caac.21457). The ACS now recommends starting screening at age 45, instead of 50. It made this change because the incidence of colon cancer in people under 50 has risen dramatically over the past 20 years. Fortunately, as younger Americans begin to be screened under the new guidelines, a new, high-tech screening test–known as virtual colonoscopy–is poised to make screening for colon cancer safer and less expensive. Regrettably, the federal agency that oversees Medicare is slowing virtual colonoscopy’s widespread adoption, harming Medicare patients and other screening-age Americans.
No one looks forward to a colonoscopy, the best known of the available screening tests for colon cancer. The patient needs to be sedated, which means taking a day off from work and asking a friend or family member for a ride home. Traditional colonoscopy also carries a small but significant risk of colon perforation. Some patients will suffer severe injury; a few will die. Thousands of colonoscopy patients experience other complications, such as bleeding, heart and lung problems and abdominal pain (https://www.asge.org/docs/default-source/education/practice_guidelines/doc-56321364-c4d8-4742-8158-55b6bef2a568.pdf). Despite these drawbacks, traditional colonoscopy was for many years the best available test for early detection of the polyps that lead to colon cancer.
Fortunately, now there’s a better alternative: virtual colonoscopy, also known as CT colonography. Virtual colonoscopy uses a non-invasive CT scan to produce a three-dimensional, computerized rendering of the inside of the colon. Unlike traditional colonoscopy, virtual colonoscopy is completely safe. It’s also at least as good as traditional colonoscopy at finding colon cancer and, most important, the pre-cancerous polyps that grow into colon cancer. Five to ten percent of virtual colonoscopy patients will need a follow-up traditional colonoscopy to remove large polyps found during screening, but the other 90% to 95% of patients will never be exposed to the risks of traditional colonoscopy.
Virtual colonoscopy is also dramatically cheaper than traditional colonoscopy. Traditional colonoscopy charges can run in to the many thousands of dollars (https://www.nytimes.com/2013/06/09/opinion/sunday/the-weird-world-of-colonoscopy-costs.html); virtual colonoscopy typically costs only $600 to $800. What’s more, this price difference omits a hidden economic benefit: Virtual colonoscopy patients can go right back to work after the test, because no sedation is required.
There are other, harder to quantify advantages, as well. Some Americans skip screening because they can’t afford to take a day off to be sedated for a traditional colonoscopy. Others avoid colonoscopies because they fear complications, such as perforation of the colon. Stool-based tests, including Cologuard, are safe and can detect colon cancer, but they’re not nearly as effective as virtual and traditional colonoscopies at finding polyps before they become cancerous–the key benefit of screening. Allowing more Americans to choose virtual colonoscopy will reduce injuries from colonoscopies, save money and encourage reluctant patients to receive effective screening.
Despite these advantages, the Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, has refused to provide coverage for virtual colonoscopy, forcing Medicare patients to choose between traditional colonoscopy and no screening at all. This puts CMS at odds with other medical organizations, including the American Cancer Society and the United States Preventive Services Task Force, the government body responsible for determining which screening tests are worthwhile. Both have endorsed virtual colonoscopy as an equally effective screening test for colon cancer.
CMS’s objection is that because the CT scan used in virtual colonoscopy provides images of other organs in the abdomen, the test can find problems outside the colon, which can lead to additional tests and treatments. One would think that finding other potentially dangerous conditions is a benefit, not a drawback; indeed, one of the authors found a previously undetected kidney cancer while reading his own virtual colonoscopy. These benefits aren’t just anecdotal: Research proves that virtual colonoscopy frequently finds cancers outside the colon, most commonly in the lung, kidney and lymph nodes. Virtual colonoscopy can also identify osteoporosis and silent aneurysms of the aorta.
Yet CMS worries that such findings outside the colon will lead to unnecessary tests and treatments for the patient, with those treatments leading to other risks. Put differently, the agency’s view is that this additional, accurate information is bad because doctors might use it unwisely. To be sure, doctors should be trained not to order unnecessary further tests or treatments; the authors train all radiologists to report only significant findings outside the colon. But the few findings from outside the colon that have resulted in further tests or treatment have been serious, and detecting them has saved lives.
Just about every private insurer already covers virtual colonoscopy; Medicare is the only holdout. Without Medicare approval, virtual colonoscopy will remain unavailable to tens of millions of older Americans. With approval, private investment–and the cascade of research and innovation that will follow as the market for virtual colonoscopy grows–will make this lifesaving technology even better. Under the new American Cancer Society guidelines millions more Americans stand to benefit from those innovations.
All physicians take an oath to promote the health of their patients–and, of course, to do them no harm. By bringing a safer, better test for colon cancer to its patients, Medicare can do both.
- Mark E. Klein, MD, FACR
Assistant Professorial Lecturer
The George Washington University Medical Center
- Perry J. Pickhardt, MD
Professor of Radiology
Chief, Gastrointestinal Imaging
Medical Director, Cancer Imaging
University of Wisconsin
School of Medicine & Public Health
- Matthew A. Barish, MD, FACR, FSAR
Director, International Symposia on Virtual Colonoscopy
Director, CT Colonography Course, ACR Education Center
Vice-Chair, Radiology, SUNY Stony Brook